Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > uses

: ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)

or Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)

or Preventive treatment of migraine in adults (episodic and chronic)

Use the filters below to narrow your results.

None (4)

Aimovig (1) · Ajovy (1) · Qelbree (1) · Sunosi (1)

Anti-CGRP ligand monoclonal antibody (1) · Anti-CGRP receptor monoclonal antibody (1) · non-stimulant ADHD agent (1) · Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) · Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1) · wake-promoting agent (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) · Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 70 mg SC monthly; may increase to 140 mg monthly (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) · Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)

100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 70 mg/mL or 140 mg/mL prefilled autoinjector (1) · 75 mg, 150 mg tablets (1)

140 mg/month (1) · 150 mg/d (1) · 400 mg/d (pediatric); 600 mg/d (adult) (1) · 675 mg/quarter (1)

Oral (2) · Subcutaneous (2)

ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) · Onset of preventive effect over weeks; some patients respond after first dose (1) · Over weeks (1) · ~30-60 min (1)

Daily dosing (1) · Monthly dosing (1) · Monthly or quarterly dosing (1) · ~9 hours (1)

~28 days (1) · ~31 days (1) · ~7 hours (1) · ~7.1 hours (1)

Adequate oral bioavailability with extended-release formulation (1) · Not formally established (1) · ~82% SC (1) · ~95% (1)

Limited data (1) · Limited data; avoid (2) · Limited data; pregnancy exposure registry available (1)

Rx (2) · Rx, '''not a controlled substance''' (no DEA scheduling) (1) · Rx, Schedule IV (US) (1)

Showing below up to 4 results in range #1 to #4.

E

Erenumab

F

Fremanezumab

S

Solriamfetol

V

Viloxazine

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"